NMDA Receptor Glycine Site Modulators for Fast-Acting Antidepressants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressants for Major Depressive Disorder (MDD) and treatment-resistant depression have limitations such as delayed onset of efficacy, low remission rates, and severe side effects, while modulators of the NMDA receptor, like ketamine and D-cycloserine, face issues with psychometric side effects and administration challenges.
Innovation Solution
Development of compounds with affinity for the glycine site of the NMDA receptor, specifically represented by compounds of Formula I, which are used in pharmaceutical compositions for treating depression, offering a potential solution with improved efficacy and tolerability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional antidepressants (SSRIs, SNRIs, MAOIs, Tricyclic) are used for treating MDD, then they provide sustained therapeutic action, but they exhibit delayed onset of efficacy and low remission rates
Solution Approach 1:
The patent changes the pharmacological parameter from conventional antidepressant mechanisms (serotonin/norepinephrine reuptake inhibition) to NMDA receptor modulation via glycine site agonism. This parameter change enables both fast onset (comparable to ketamine) and sustained action (unlike single-dose ketamine), resolving the time-related contradiction
2Speed
If ketamine is used for treating MDD, then fast onset of antidepressant effect is achieved, but psychometric side effects and requirement of intravenous administration occur
Solution Approach 1:
The patent applies local quality by selectively targeting the glycine site on the NMDA receptor with high affinity and selectivity, rather than non-selective NMDA antagonism. This localized action at a specific receptor site produces fast antidepressant onset while minimizing off-target psychometric side effects associated with broader NMDA receptor blockade
Solution Approach 2:
The patent copies the beneficial fast-onset property of ketamine (NMDA modulation) while eliminating its harmful aspects by using a different mechanism (glycine site agonism vs. competitive antagonism) and oral administration route, creating a simplified version that retains the core advantage without the drawbacks
3Reliability
If D-cycloserine is used as NMDA receptor modulator, then affinity for glycine site is achieved, but frequent psychopathological stimulation side effects occur
Solution Approach 1:
The patent optimizes the chemical structure parameters of glycine site agonists by introducing specific substituents (aromatic groups, heterocycles, fluorinated alkyl chains) to enhance binding affinity and selectivity while modulating pharmacokinetic properties. This structural parameter optimization reduces side effects compared to D-cycloserine while maintaining reliable glycine site affinity
Solution Approach 2:
The patent creates composite molecular structures combining the glycine site agonist core with various aromatic and heterocyclic substituents (thieno[3,2-b]pyridine, indole, benzofuran groups). These composite structures improve pharmacological profile by enhancing receptor affinity while reducing psychopathological side effects through better selectivity and metabolic stability
Data Source
AI summary
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.